一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括Pomalidomide Capsules；Bortezomib for Injection；Daratumumab Injection (Subcutaneous Injection)；IBI3003；Selinexor Tablets，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pomalidomide Capsules；Bortezomib for Injection；Daratumumab Injection (Subcutaneous Injection)；IBI3003；Selinexor Tablets · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- ZhongShan Hospital FuDan University · 上海
公开的入选条件
- 1. Age ≥18 years.
- 2. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria.
- 3. At least one of the following measurable disease indicators:
- Serum M-protein ≥ 5 g/L（For IgA and IgD subtypes, it is recommended to use quantitative immunoglobulin measurements instead of M protein）
- Urine M-protein ≥200 mg/24h
- Serum free light chain (FLC) test: affected FLC level ≥100 mg/L and abnormal serum FLC ratio (\<0.26 or \>1.65)
- 4. Life expectancy ≥3 months.
- 5. Fertile females and sexually active fertile males must agree to use highly effective contraception (failure rate \<1% per year) during the study and for 90 days after the last dose of the investigational drug. For participants in the clinical trial, contrac
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07623798；登记信息更新于 2026-09-17。